Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
securities law
Pharma
SEC tags BeiGene, Hutchmed, Zai Lab for potential delisting
The three Chinese biotechs have three years to comply with a newly installed foreign audit law or face delisting from the U.S. stock exchanges.
Angus Liu
Mar 11, 2022 10:32am
SEC pokes around FibroGen's roxadustat safety data
Mar 1, 2022 11:46am
Biocon-Viatris, AstraZeneca, Huhai and more—Fierce Pharma Asia
Nov 19, 2021 8:20am
Regulator's initial probe clears Sun Pharma of fraud: report
Aug 29, 2019 12:10pm
Korea Exchange offices raided in Samsung BioLogics IPO probe
Mar 15, 2019 11:30am
Indian regulators confirm whistleblower complaint against Sun
Dec 13, 2018 12:13pm
